Theriva Biologics Inc
TOVX
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.78M
Close$
$0.86
259.3% upside
Current Fair Value
259.3% upsideUndervalued by 259.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $10.78 Million |
|---|---|
| Enterprise Value | $3.00 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.08 |
| Beta | 1.12 |
| Outstanding Shares | 45,892,668 |
Return
| Return on Equity | -107.72% |
|---|---|
| Return on Assets | -37.66% |
| Return on Invested Capital | -52.18% |
Valuation & Multiples
| P/E Ratio | -0.35 |
|---|---|
| PEG | 0.47 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 10 |
| Enterprise Value to EBIT | -0.25 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.18 |
| Debt to Equity | 0.29 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
$300,000
Average shareholder expectationNext Earnings Call
Expected Date
November 17, 2026
EPS Estimate
$-0.07
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 4.78%▼ 5.89% |
|---|---|
| Total Invested | $385,352▲ 41.48% |
| Investors Holding | 200% |
ESG Score
No data
About Theriva Biologics Inc
10 employees
CEO: Steven Shallcross Synthetic Biologics, Inc. is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company's lead candidates ...